May 10th 2024
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
May 9th 2024
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
May 8th 2024
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
Your daily dose of the clinical news you may have missed.
May 2nd 2024
Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.